Navigation Links
Introducing Strativa Pharmaceuticals
Date:9/28/2007

nd other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issue described in this and prior public announcements, including the lawsuit brought against the company by the trustee for the company's Senior Subordinated Convertible Notes seeking an accelerated payment of the $200 million of principal of and accrued interest on the notes or, in the alternative, damages, the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission (SEC), such as the company's reports on Form 10-K, Form 10-Q, and Form 8-K, and amendments thereto. The company can make no assurance as to the potential effects of the restatement, including the effects of any investigations, informal or otherwise, conducted by the SEC, or other entities, or lawsuits filed against the company in connection therewith. Any forward-looking statements included in this press release are made as of the date here of only, based on information available to the company as of the date hereof, and, subject to any applicable law to the contrary, the company assume
'/>"/>

SOURCE Strativa Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Introducing GenElute HP Endotoxin-Free Plasmid Maxiprep Kit
2. Johnson Controls introducing new building controls system
3. Deltanoid Pharmaceuticals begins phase II osteoporosis study
4. The Coming of Biotech Generic Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., ... discovery and development of proprietary new molecular entity ... Patent and Trademark Office (USPTO) issued U.S. Patent ... entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl ... Making and Use Thereof." The patent, ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2Global Next-generation Sequencing Trends 2
... microRNA Technology Submitted for, Regulatory Approval to the New York State Department of ... University ... ... Two Additional microRNA-Related Patents Allowed, REHOVOT, Israel and ...
... 21 Daiichi Sankyo Co., Ltd. announced today,that it ... held firm,U3 Pharma AG, a German biotechnology company focusing ... Daiichi Sankyo will purchase 100 percent of the stock ... million dollars) for the,company. Closure of the transaction is ...
... May 20 NASA has,developed a revolutionary nanotechnology-based ... viruses and parasites. This biosensor,will be used to ... in,water, food and other contaminated sources., NASA,s ... licensed the,biosensor technology to Early Warning Inc., Troy, ...
Cached Biology Technology:Rosetta Genomics Reports First Quarter 2008 Financial Results 2Rosetta Genomics Reports First Quarter 2008 Financial Results 3Rosetta Genomics Reports First Quarter 2008 Financial Results 4Rosetta Genomics Reports First Quarter 2008 Financial Results 5Rosetta Genomics Reports First Quarter 2008 Financial Results 6Rosetta Genomics Reports First Quarter 2008 Financial Results 7Rosetta Genomics Reports First Quarter 2008 Financial Results 8Rosetta Genomics Reports First Quarter 2008 Financial Results 9Rosetta Genomics Reports First Quarter 2008 Financial Results 10Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3NASA Nanotechnology-Based Biosensor Helps Detect Biohazards 2
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
(Date:9/29/2014)... of gut bacteria called Clostridium ramosum , coupled with ... work is published this week in mBio , the ... , A research team from the German Institute of Human ... bacteria including C. ramosum gained weight when fed ... ramosum were less obese even when consuming a high-fat ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... State University doctoral student Jennifer Smith has shed new light ... importantly hunt for their food alone. In a ... Smith, a student in MSU,s Department of Zoology, shows that ... large, cooperative societies, they also realize that venturing on their ...
... terranes comprise a huge portion of real estate in ... containing rocks and fossils very different from those in ... mixed rocks, tectonic styles, metamorphism, and volcanic origins, much ... puzzle, this new Geological Society of America Special Paper ...
... to purchase a powerful $2 million computer that will ... diagnose and treat brain disease, heart illnesses, cancer and ... Medicine, based at Johns Hopkins, Homewood campus in Baltimore, ... for 2008 awarded by the National Center for Research ...
Cached Biology News:Spotted hyenas can increase survival rates by hunting alone 2$2 million computer will help unravel major medical ailments 2$2 million computer will help unravel major medical ailments 3
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... minor groove-binding probe for DNA. Binds to ... to AT rich DNA), forming a stable ... than DAPI alone. DAPI is several times ... DNA in agarose gels. It may be ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Biology Products: